CARsgen and Galapagos Resume CAR-T Trials Without Restrictions

CAR-T Trials Resumption:
CARsgen and Galapagos have announced that their CAR-T trials are now running without restrictions, indicating a significant step forward in their clinical research programs.

Galapagos' CAR-T Programs:
Galapagos is currently working on three clinical CAR-T programs, including GLPG5101 for relapsed or refractory non-Hodgkin lymphoma, GLPG5201 for chronic lymphocytic leukemia and Richter transformation, and GLPG5301 for multiple myeloma.

FDA Clearance:
The FDA has cleared Galapagos' IND application for the Phase 1/2 ATALANTA-1 study of GLPG5101, allowing the company to proceed with evaluating the CAR-T therapy in the U.S. for relapsed/refractory non-Hodgkin lymphoma.

Decentralized Manufacturing:
Galapagos has partnered with Blood Centers of America to decentralize the manufacturing of CAR-T therapies, aiming to deliver fresh, fit cells with a median vein-to-vein time of seven days, closer to treatment centers across the U.S..

Early Data:
Early data from the ATALANTA-1 study presented at the European Hematology Association 2024 Congress showed promising results, with high response rates and encouraging safety profiles.